Skip to main content
78kviews
Editorial03 February 2022
Editorial: Interferons and GvHD
Boram Kimand Jaebok Choi

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective treatment and curative approach for patients with hematological malignancies. However, despite the life-saving benefits of allo-HSCT, such as graft-versus-leukemia (GvL) effects and healthy immune reconstitution, a majority of patients develop graft-vs-host-disease (GvHD), leading to organ/tissue damages in the skin, liver, and GI tract. For that reason, extensive researches on GvHD have been made and identified IFNs as therapeutic targets. Nonetheless, the pleiotropic nature of IFNs has hindered our goals to optimally control GvHD.The goals of the articles collected in the Research Topic are to define the roles and mechanisms of IFNs in GvHD and to provide insights into novel therapeutic approaches to restrain GvHD while enhancing the benefits of allo-HSCT.To expand the investigation on mechanisms of primary human T cell responses in GvHD, xenogeneic cell transplant models have been utilized. In depth, Hess et al. highlighted that the development of humanized mouse models and xenogeneic transplant model system, which benefit from the human T cell receptors (TCRs) having cross-reactivity to murine MHC in addition to cytokines and co-stimulatory proteins, has led to investigation on human T cell biology. Hess et al. further explained the importance of TCR and the ability to recognize non-self-antigens on MHC, cellular therapy by suppressing or enhancing the secretion of cytokines and co-stimulatory/inhibitory signaling pathways.In the review by Zhao et al. the authors discussed the effects of IFNs on T cell and their function and epigenetic regulations during GvHD. They elaborated the paradoxical roles of IFNs in alloreactive T cell differentiation and function and the development of GvHD. The process of GvHD is also critically controlled by epigenetic regulators, such as DNA methylation, histone modification, and chromatin remodeling. In turn, these regulators modulate T cell differentiation and function by influencing IFN signaling and therapeutic potentials. Conclusively, the authors suggest future studies on epigenetic mechanisms of IFNs to better understand how IFNs regulate GvHD.Not only essential for differentiation and expansion of immune cells, IFNs play an important role in the GI tract. Haring et al. explored the pathophysiology of GvHD caused by the imbalance of cytokine network in the GI tract. The authors summarize that similar to IBD, type Ⅰ and type III IFNs are important for maintaining the intestinal epithelial barrier integrity and controlling immune responses in GvHD. However, the conditioning regimen prior to allo-HSCT damages the epithelial cells resulting in the release of DAMPs and PAMPs, leading to local inflammation together with inflammatory cytokines and activation of APCs. This in turn results in the activation and expansion of the alloreactive T cells causing further tissue destruction and inflammation together with cytokines including type II IFN and chemokines in the GI tract. Overall, the review shows the highly complex and interconnected cytokines network and the effect of its imbalance on intestinal mucosal inflammation, suggesting that identifying targets downstream of IFNs and receptors might provide novel therapeutic strategies for GvHD and IBD.The use of JAK inhibitors is a promising therapeutic strategy for GvHD and cytokine release syndrome. Assal and Mapara comprehensively reviewed the role of the JAK/STAT pathway in T cell activation and expansion, APC function, and Tregs expansion. The knowledge led to the idea of disrupting the JAK/STAT pathway by using ruxolitinib or baricitinib to ameliorate GvHD. Clinical evidence has also shown that ruxolitinib administration to GvHD patients has been successful. The study by Wang et al. also showed similar results; in the retrospective study, 70 Chinese patients with steroid-refractory chronic GvHD (SR-cGvHD) received ruxolitinib, then the overall response, complete remission, and partial remission rates were examined. Twenty-four weeks after ruxolitinib treatment, those rates were significantly improved, compared to those of the patient group without ruxolitinib treatment. The authors also showed that CD4 + cells, total B cells, and IL-10 were significantly increased after the treatment, whereas NK cells, Tregs, and ST2 were significantly decreased. Collectively, these results suggest that ruxolitinib is a safe and effective treatment for SR-cGvHD.Targeting TCR and co-stimulatory pathways also serves as a therapeutic strategy to control GvHD. In the review by Lutfi et al. authors illustrated the CD27-CD70 co-stimulatory pathway and its therapeutic potential in combination with immune checkpoint inhibitors and in GvHD. The CD27-CD70 pathway leads to survival and activation of T, B, and NK cells, and the activity is shown to be increased under proinflammatory conditions and IFN-γ secretion. With the understanding of its nature, studies to targeting the CD27-CD70 pathway to improve outcomes have been made. For instance, a CD27 agonizing monoclonal antibody, varlilumab, showed to improve antineoplastic response in combination with immune checkpoint inhibitors by enhancing CD8 + T cell expansion and proliferation. On the other hand, an administration of anti-CD70 monoclonal antibody and CD70 KO mice resulted in increased GvHD. Further studies explained that while APC-expressed CD70 provides a co-stimulatory signal, T-cell-expressed CD70 served an inhibitory role in T-cell response. These findings proposed that this complex mechanism may provide a potential therapeutic intervention as an oncologic therapy and to attenuate GvHD by modulating the pathway.Previous studies suggest that recombinant human LYG1 protein (rhLYG1) can promote the activation and IFN-γ production of CD4 + T cells, thereby inhibiting tumor growth. Liu et al. in turn hypothesized that LYG1 participated in the development of GvHD and explored the role and mechanisms of LYG1 during GvHD. As hypothesized, the study discovered that LYG1 deficiency in donor T cells reduced the severity of GvHD. In depth, LYG1 deficiency in donor T cells inhibited the activation of CD4 + T cells and expression of IFN-γ, while promoting the expression of FOXP3, thereby suppressing the expression of CXCL9 and CXCL10 and the infiltration of allogeneic CD4 + T cells into target organs. Despite of a modest improvement in the overall survival by LYG1 blockade, these findings demonstrate that targeting LYG1 may be as a potential therapeutic strategy to reduce GvHD. Huisman et al. provide significant insight on the risk of off-target toxicity via allo-HLA across-reactivity. Using third-party donor-derived virus-specific T cells, Huisman et al. investigated whether HLArestriction, HLA background, and/or virus-specificity could predict the risk of allo-HLA cross-reactivity. The results demonstrated that HLA-B*08:01-restricted T cells, had the highest allo-HLA cross-reactivity regardless of virus-specificity, suggesting a potential strategy to reduce the risk of off-target toxicity by selecting T cells with a specific HLA restriction and background.Overall, the articles in the Research Topic provided sufficient reviews on the recent advances in the roles of IFNs in GvHD and highlighted promising therapeutic strategies, such as CD27 agonizing monoclonal antibodies, JAK inhibitors, and targeting LYG1, to modulate IFN signaling to restrain GvHD while preserving the benefits of all-HSCT. Indeed, further researches should be followed to reveal the exact mechanisms of IFNs in the context of transplantation to provide promising transplantation therapies.

1,949 views

CORRECTION
16 September 2021
Corrigendum: LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells
Huihui Liu, 12 more and Yujun Dong

2,001 views

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
ORIGINAL RESEARCH
30 June 2021
Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
Dong Wang, 7 more and Yang Xu
Graft-versus-host disease (GVHD), especially steroid-refractory GVHD, remains a life-threatening complication after hematopoietic stem cell transplantation (HSCT). The effect of the JAK1/2 kinase inhibitor ruxolitinib on treating steroid-refractory acute GVHD has been verified by the REACH1/2 study; however, its safety and efficacy in patients with steroid-refractory chronic GVHD (SR-cGVHD) remain unclear. In this retrospective study, 70 patients received ruxolitinib as a salvage therapy for SR-cGVHD. Twenty-four weeks after ruxolitinib treatment, the overall response rate (ORR) was 74.3% (52/70), including 34 patients who achieved complete remission (CR) and 18 who achieved partial remission (PR). The main adverse event was cytopenia, which occurred in 51.4% (36/70) of patients. After ruxolitinib treatment, the percentage of CD4 cells increased from 18.20% to 23.22% (P<0.001), while the percentages of NK (CD16+CD56+) cells and regulatory T cells (CD4+CD127±CD25+) decreased (P<0.001, P<0.001). Among the B cell subsets, the proportion of total B cells approximately tripled from 3.69% to 11.16% (P<0.001). Moreover, we observed a significant increase in IL-10 levels after ruxolitinib treatment (P=0.025) and a remarkable decrease in levels of suppression of tumorigenicity 2 (ST2) from 229.90 ng/ml to 72.65 ng/ml. The median follow-up after the initiation of ruxolitinib treatment was 401 (6-1076) days. The estimated one-year overall survival rate of the whole group was 66.0% (54.4–77.6%, 95% CI), and the one-year overall survival rate of patients with mild and moderate cGVHD was 69.6% (57.4–81.8%, 95% CI), which was better than that of patients with severe cGVHD (31.3%, 0.0–66.2%, 95% CI) (P=0.002). Patients who achieved a CR and PR achieved better survival outcomes (84.5%, 73.9–95.1%, 95% CI) than those who showed NR to ruxolitinib treatments (16.7%, 0–34.3%, 95% CI) (P<0.001). At the final follow-up, cGVHD relapse occurred in six patients after they reduced or continued their ruxolitinib doses. Collectively, our results suggest that ruxolitinib is potentially a safe and effective treatment for SR-cGVHD.

7,625 views

20 citations

ORIGINAL RESEARCH
28 June 2021
LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells
Huihui Liu, 12 more and Yujun Dong

3,753 views

7 citations

ORIGINAL RESEARCH
29 March 2021
Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells Is Dictated by HLA-Restriction
Wesley Huisman, 5 more and Inge Jedema

4,382 views

22 citations